Nektar boosts R&D presence in San Francisco

Nektar Therapeutics ($NKTR) has announced a move to consolidate all of its U.S. research and development at its Mission Bay location in San Francisco. The company, a maker and developer of PEGylated drugs, plans to relocate 30 R&D workers from its research site in Huntsville, AL, to Mission Bay by July as part of the move. The company plans to keep manufacturing operations in Alabama, however. The San Francisco Business Times reports that the company, which will also keep its research outpost in India, plans to cut 5 jobs in Alabama. Article



Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.